CN113347976A - 用牛磺罗定水解产物进行的神经母细胞瘤治疗 - Google Patents

用牛磺罗定水解产物进行的神经母细胞瘤治疗 Download PDF

Info

Publication number
CN113347976A
CN113347976A CN201980071416.3A CN201980071416A CN113347976A CN 113347976 A CN113347976 A CN 113347976A CN 201980071416 A CN201980071416 A CN 201980071416A CN 113347976 A CN113347976 A CN 113347976A
Authority
CN
China
Prior art keywords
composition
tauramide
neuroblastoma
hydrothiadiazine
administered
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201980071416.3A
Other languages
English (en)
Chinese (zh)
Inventor
B·雷登伯格
R·狄卢西奥
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cormedix Inc
Original Assignee
Cormedix Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cormedix Inc filed Critical Cormedix Inc
Publication of CN113347976A publication Critical patent/CN113347976A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/549—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame having two or more nitrogen atoms in the same ring, e.g. hydrochlorothiazide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5146—Organic macromolecular compounds; Dendrimers obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5146—Organic macromolecular compounds; Dendrimers obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides
    • A61K9/5153—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Optics & Photonics (AREA)
  • Nanotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Biomedical Technology (AREA)
  • Dermatology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN201980071416.3A 2018-08-28 2019-08-28 用牛磺罗定水解产物进行的神经母细胞瘤治疗 Pending CN113347976A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862723618P 2018-08-28 2018-08-28
US62/723618 2018-08-28
PCT/US2019/048592 WO2020047113A1 (en) 2018-08-28 2019-08-28 Neuroblastoma treatment with taurolidine hydrolysis products

Publications (1)

Publication Number Publication Date
CN113347976A true CN113347976A (zh) 2021-09-03

Family

ID=69645349

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201980071416.3A Pending CN113347976A (zh) 2018-08-28 2019-08-28 用牛磺罗定水解产物进行的神经母细胞瘤治疗

Country Status (7)

Country Link
EP (1) EP3843746A4 (https=)
JP (2) JP2021535163A (https=)
KR (1) KR20210050544A (https=)
CN (1) CN113347976A (https=)
AU (1) AU2019330954B2 (https=)
CA (1) CA3111057A1 (https=)
WO (1) WO2020047113A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116769723A (zh) * 2023-08-09 2023-09-19 山东省成体细胞产业技术研究院有限公司 一种gd2嵌合抗原受体修饰的t细胞及其应用

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113226325A (zh) * 2018-08-31 2021-08-06 科医公司 牛磺罗定对哺乳动物体内表达myc的肿瘤的治疗
CA3140981A1 (en) * 2019-05-22 2020-11-26 Geistlich Pharma Ag Oxathiazin compounds for inhibiting gapdh

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5602150A (en) * 1992-10-02 1997-02-11 Research Foundation For Mental Hygiene, Inc. Treatment of central nervous system disorders associated with psychotic behavior and dementia with a combination of neuroleptic drugs and taurine, or derivatives thereof, to prevent the development of tardive dyskinesia
US6521616B2 (en) * 1999-12-06 2003-02-18 Rhode Island Hospital, A Lifespan Partner Methods of treating tumors with taurolidine
DE60311958D1 (de) * 2003-02-03 2007-04-05 Polaschegg Hans Dietrich Zusammensetzung zur Prävention von Infektionen durch subkutane Prothesen
CN103118669A (zh) * 2010-06-01 2013-05-22 盖斯特里希医药公司 口服药物治疗方法和组合物
CN104244949A (zh) * 2012-03-30 2014-12-24 诺华股份有限公司 用于治疗神经母细胞瘤、尤文氏肉瘤或横纹肌肉瘤的化合物
US20170196875A1 (en) * 2016-01-11 2017-07-13 Cormedix Inc. Therapeutic nanoparticles for the treatment of neuroblastoma and other cancers

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030027818A1 (en) * 2001-04-03 2003-02-06 Redmond H. Paul Treatment of cancers
US20050096314A1 (en) * 2001-04-03 2005-05-05 Ed. Geistlich Soehne Ag Fuer Chemische Industrie Treatment of cancers with methylol-containing compounds and at least one electrolyte
CN100519525C (zh) * 1999-12-06 2009-07-29 葛兰素集团有限公司 芳香砜类及其医疗用途
CA2363973C (en) * 2000-11-28 2009-03-10 Ed. Geistlich Sohne Ag Fur Chemische Industrie Enhancement of effectiveness of 5-fluorouracil in treatment of tumor metastases and cancer
US20080177217A1 (en) * 2004-05-14 2008-07-24 Hans-Dietrich Polaschegg Taurolidine Formulations and Delivery: Therapeutic Treatments and Antimicrobial Protection Against Bacterial Biofilm Formation
ES2377206T3 (es) * 2006-01-06 2012-03-23 Ed Geistlich Sohne Ag Fur Chemische Industrie Composiciones irradiadas y tratamiento de cánceres con radiación en combinación con taurolidina y/o taurultam

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5602150A (en) * 1992-10-02 1997-02-11 Research Foundation For Mental Hygiene, Inc. Treatment of central nervous system disorders associated with psychotic behavior and dementia with a combination of neuroleptic drugs and taurine, or derivatives thereof, to prevent the development of tardive dyskinesia
US6521616B2 (en) * 1999-12-06 2003-02-18 Rhode Island Hospital, A Lifespan Partner Methods of treating tumors with taurolidine
DE60311958D1 (de) * 2003-02-03 2007-04-05 Polaschegg Hans Dietrich Zusammensetzung zur Prävention von Infektionen durch subkutane Prothesen
CN103118669A (zh) * 2010-06-01 2013-05-22 盖斯特里希医药公司 口服药物治疗方法和组合物
CN104244949A (zh) * 2012-03-30 2014-12-24 诺华股份有限公司 用于治疗神经母细胞瘤、尤文氏肉瘤或横纹肌肉瘤的化合物
US20170196875A1 (en) * 2016-01-11 2017-07-13 Cormedix Inc. Therapeutic nanoparticles for the treatment of neuroblastoma and other cancers

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116769723A (zh) * 2023-08-09 2023-09-19 山东省成体细胞产业技术研究院有限公司 一种gd2嵌合抗原受体修饰的t细胞及其应用
CN116769723B (zh) * 2023-08-09 2023-11-03 山东省成体细胞产业技术研究院有限公司 一种gd2嵌合抗原受体修饰的t细胞及其应用

Also Published As

Publication number Publication date
EP3843746A4 (en) 2022-10-19
JP2024170590A (ja) 2024-12-10
CA3111057A1 (en) 2020-02-05
AU2019330954A1 (en) 2021-04-22
WO2020047113A1 (en) 2020-03-05
AU2019330954B2 (en) 2025-11-13
JP2021535163A (ja) 2021-12-16
EP3843746A1 (en) 2021-07-07
KR20210050544A (ko) 2021-05-07

Similar Documents

Publication Publication Date Title
US11253600B2 (en) Bioorthogonal compositions
JP2024170590A (ja) タウロリジン加水分解産物による神経芽細胞腫治療
CN1596127A (zh) 包含多阳离子聚合物和负电荷的药理学活性化合物的控释药物传递组合物
JP2014531456A (ja) 治療用ナノ粒子と癌を治療する方法
SA516371814B1 (ar) جسيمات نانوية علاجية تشمل عامل علاجى وطرق صنعها وإستخدامها
US20230390300A1 (en) Neuroblastoma treatment with taurolidine hydrolysis products
JP2021523173A (ja) 生物応答性ヒドロゲルマトリックス及び使用方法
CN119947713A (zh) 用于精准癌症治疗的组合物及精准癌症治疗方法
US20220323450A1 (en) Methods and compositions for treating neuroblastoma in a juvenile mammalian body
CN113905764B (zh) 用于治疗癌症的前体半胱天冬酶-3活化作用和免疫疗法
CN113164491A (zh) 用于治疗幼年哺乳动物体内神经母细胞瘤的方法和组合物
US20250144111A1 (en) Taurolidine treatment for myc-expressing tumors in mammalian bodies
CN113226325A (zh) 牛磺罗定对哺乳动物体内表达myc的肿瘤的治疗
US12611461B2 (en) Bioorthogonal compositions
Zhang et al. polypeptide-based micelles for
Fymat Oncogenomics: A personalized cancer therapy
HK40118230A (en) Bioorthogonal compositions
HK1070581A (en) Controlled release drug delivery composition comprising polycationic polymer and negatively charged pharmacologically active compound

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination